Press release
Biosimilar Market is Predicted to Witness a Significant CAGR during the forecast period 2020-2027 | Research Report Size, Share & Forecast
Biosimilar MarketThe Biosimilar Market is estimated to expand at a significant CAGR during the forecast period (2020-2027).
The factors driving the growth of Biosimilar Market includes rising prevalence of chronic diseases around the world, growing emphasis by Governments on reducing the expenditure on healthcare, cost effectiveness of biosimilar drugs and increasing geriatric population. According to the report published by World Health Organization (WHO), the population aged 60 and above worldwide was calculated around 1 billion in 2019 and this figure is predicted to reach 1.4 billion by the end of 2030, which will accelerate the demand for biosimilar drugs in the approaching years. Moreover, expiry of blockbuster biologics increasing partnership between pharmaceutical and biotech companies and growing demand for cost-effective medicines across the globe, are some of the additional factors supplementing the Biosimilar Market Growth. In addition, increasing investments by major corporations on research and development, rising disposable incomes, rapid urbanization, and improvements in the living standards, are further pushing the Biosimilar Market share.
For More Info, Click to Access Complete Report - https://www.gmiresearch.com/report/global-biosimilar-market/
However, the growth of Biosimilar Market is hindered due to complexities in the manufacturing of biosimilars.
The major players operating in the market are Celltrion Healthcare Co., Ltd., Samsung Biologics, Amgen Inc., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly, and Company, Biocon, and Viatris Inc., among others.
Based on Product, the Monoclonal Antibodies segment is predicted to grow at a remarkable CAGR over the forecast period
According to the Biosimilar Market Forecast, increasing use of monoclonal antibodies by biotech companies for treating cancer, diabetes, and autoimmune diseases along with monoclonal, are propelling the segment's growth.
Based on Indication, the Indication segment is projected to grow at a robust CAGR during the forecast period
As per the Biosimilar Market Report, rise in the launches of innovative products and growing investments by pharmaceutical companies on research and development, are some of the factors augmenting the segment's growth.
Based on Region, the European region is anticipated to hold the highest market share during the forecast period
Presence of the leading pharmaceutical companies, rising incidences of chronic diseases, growing geriatric population, increase in the launch of innovative products and high per capita incomes, are some of the important factors augmenting the Biosimilar Market size in Europe.
Key Developments:
In 2020, Pfizer Inc. introduced three new biosimilars in the United States, ZIRABEV™ (bevacizumab-bvzr), RUXIENCE™ (rituximab-pvvr) and TRAZIMERA™ (trastuzumab-qyyp).
In 2020, Sandoz International GmbH introduced two biosimilars in the Canadian pharmacies and hospitals namely Riximyo and Ziextenzo.
Market Segmentation
Segmentation by Product
Insulin
Monoclonal Antibodies
Erythropoietin
Granulocyte Colony-Stimulating Factor
Etanercept
Recombinant Human Growth Hormone
Teriparatide
Follitropin
Interferons
Enoxaparin Sodium
Calcitonin
Glucagon
Segmentation by Type of Manufacturing
Contract Manufacturing
In-House Manufacturing
Segmentation by Indication
Chronic Diseases
Oncology
Blood Disorders
Autoimmune Diseases
Infectious Diseases
Growth Hormone Deficiency
Other Indications
Segmentation by Region
Asia Pacific
China
Japan
India
Rest of APAC
North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Spain
Rest of Europe
RoW
Brazil
South Africa
Saudi Arabia
UAE
About GMI Research
GMI Research is a market research and consulting firm which provides market insights and intelligence across 12 major sectors helping our clients in making effective investment and business decisions.
Media Contact
Company Name: GMI RESEARCH
Contact Person: Sarah Nash
Email: enquiry@gmiresearch.com
Phone: Europe - +353 1 442 8820; US - +1 860 881 2270
Address: Dublin, Ireland
Website: https://www.gmiresearch.com/
Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate, Dublin D18 Y3X2, Ireland
Biosimilar Market is Predicted to Witness a Significant CAGR during the forecast period 2020-2027 | Research Report Size, Share & Forecast
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Market is Predicted to Witness a Significant CAGR during the forecast period 2020-2027 | Research Report Size, Share & Forecast here
News-ID: 2733360 • Views: …
More Releases from GMI Research
OLED Market is projected to rise at a higher CAGR during the forecast period | S …
The OLED Market is anticipated to expand at a remarkable CAGR during the forecast period
For Additional Insights, Click to Access Complete Report -
https://www.gmiresearch.com/report/global-oled-market/
The factors driving growth of the OLED Market includes increasing penetration of smartphones and gaming consoles around the world, Government policies supporting OLED lighting research, growing popularity of smart Televisions and improvements in the living standards. For instance, the revenue generated from the sales of video game consoles…
3D Printed Drugs Market is growing at a CAGR of 4.2% over the forecast period | …
The 3D Printed Drugs Market is growing at a CAGR of 4.2% over the forecast period.
For Additional Insights, Click to Access Complete Report - https://www.gmiresearch.com/report/global-3d-printed-drugs-market-by-technique-type/
The factors driving growth of the 3D Printed Drugs Market includes increasing geriatric population around the world, growing demand for soluble drugs, rising prevalence of stroke, Alzheimer's disease and head and neck tumors and improvements in the living standards. For instance, the population aged 60 and…
Virtual Private Cloud Market is expected to grow at a higher CAGR of 23.4% over …
The Virtual Private Cloud Market is projected to grow at a CAGR of 23.4% over the forecast period.
For Additional Insights, Click to Access Complete Report - https://www.gmiresearch.com/report/global-virtual-private-cloud-market/
The factors driving growth of the Virtual Private Cloud Market includes huge volumes of data generated across BSFI, Healthcare and Media & Entertainment industries, rising focus by companies on modernizing IT infrastructure, Government initiatives promoting digitalization, increasing number of data breaches reported around the…
Pest Control Services Market is poised to grow at a robust CAGR during the forec …
The Pest Control Services Market is estimated to grow at a robust CAGR over the forecast period
For Additional Insights, Click to Access Complete Report -
https://www.gmiresearch.com/report/pest-control-services-market/
The factors driving growth of market includes increasing demand for pest control services from hospitality, pharmaceutical, and food processing industries, growing focus on using biocides, rising concerns related to climate change, and improvements in the living standards. For instance, the market value of biocides worldwide was…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
